
  
    
      
        Background_NNP
        A_DT synthetic_JJ form_NN of_IN EPO_NNP ,_, human_JJ recombinant_JJ EPO_NNP ,_, has_VBZ been_VBN
        successfully_RB used_VBN to_TO treat_VB anemia_NN in_IN patients_NNS with_IN chronic_JJ
        renal_JJ failure_NN and_CC HIV_NNP [_NN 1_CD ]_NN ._. Some_DT randomized_JJ trials_NNS (_( RCT_NNP )_)
        assessed_VBD the_DT role_NN of_IN EPO_NNP in_IN anemia_NN related_VBD the_DT cancer_NN [_NN 2_CD 3_CD
        ]_NN ._. However_RB ,_, many_JJ of_IN these_DT trials_NNS were_VBD underpowered_JJ and_CC
        failed_VBD to_TO identify_VB clinically_RB meaningful_JJ benefits_NNS of_IN EPO_NNP
        treatment_NN ._. As_IN a_DT result_NN ,_, there_EX has_VBZ been_VBN persistent_JJ
        uncertainty_NN about_IN the_DT efficacy_NN of_IN EPO_NNP as_IN a_DT treatment_NN for_IN
        cancer-related_JJ anemia_NN ,_, despite_IN the_DT introduction_NN of_IN EPO_NNP in_IN a_DT
        clinical_JJ practice_NN almost_RB a_DT decade_NN ago_RB ._. Systematic_NNP reviews_NNS
        (_( SR_NNP )_) are_VBP the_DT best_JJS way_NN to_TO offer_VB synthesis_NN of_IN evidence_NN and_CC
        are_VBP of_IN special_JJ utility_NN in_IN settings_NNS where_WRB many_JJ small_JJ trials_NNS
        fail_VBP to_TO achieve_VB a_DT significant_JJ result_NN [_NN 4_CD ]_NN ._.
        A_DT recent_JJ comprehensive_JJ SR_NNP [_NN 5_CD 6_CD ]_NN addressed_VBD the_DT role_NN of_IN
        EPO_NNP in_IN treatment-related_JJ anemia_NN in_IN cancer_NN patients_NNS ._. This_DT SR_NNP
        included_VBD non-randomized_JJ studies_NNS and_CC performed_VBD a_DT
        meta-analysis_JJ (_( MA_NNP )_) of_IN 12_CD RCTs_NNP showing_VBG a_DT significant_JJ effect_NN
        of_IN EPO_NNP in_IN reducing_VBG the_DT need_NN to_TO transfuse_NN patients_NNS who_WP are_VBP
        receiving_VBG chemotherapy_NN ._. Although_IN comprehensive_JJ ,_, some_DT issues_NNS
        were_VBD not_RB addressed_VBN in_IN this_DT previous_JJ SR_NNP /_NN MA_NNP :_: a_DT formal_JJ
        quantitative_JJ synthesis_NN (_( meta-analysis_JJ )_) was_VBD not_RB performed_VBN
        according_VBG to_TO different_JJ clinical_JJ aspects_NNS and_CC to_TO main_JJ
        methodological_JJ quality_NN dimensions_NNS empirically_RB linked_VBN to_TO
        bias_NN [_NN 7_CD ]_NN ._.
        In_IN contrast_NN to_TO this_DT previous_JJ report_NN [_NN 5_CD 6_CD ]_NN ,_, in_IN this_DT SR_NNP
        we_PRP evaluated_VBD only_RB data_NNS from_IN randomized_JJ studies_NNS ._. We_PRP also_RB
        investigated_VBD a_DT broad_JJ range_NN of_IN clinical_JJ issues_NNS ,_, including_VBG
        EPO_NNP use_NN according_VBG to_TO the_DT level_NN of_IN hemoglobin_NN (_( hb_NN )_) ,_,
        platinum-based_JJ chemotherapy_NN and_CC tumor_NN type_NN ._. Finally_RB ,_, to_TO
        investigate_VB the_DT stability_NN of_IN our_PRP$ conclusions_NNS ,_, a_DT broad_JJ
        methodological_JJ appraisal_NN of_IN the_DT quality_NN of_IN the_DT trials_NNS was_VBD
        performed_VBN ,_, specifically_RB examining_VBG those_DT dimensions_NNS that_WDT
        have_VBP been_VBN empirically_RB linked_VBN to_TO bias_NN [_NN 7_CD ]_NN ._.
        We_PRP also_RB performed_VBD a_DT conservative_JJ cumulative_JJ
        meta-analysis_JJ (_( CMA_NNP )_) [_NN 8_CD ]_NN to_TO determine_VB the_DT earliest_JJS point_NN
        in_IN time_NN when_WRB the_DT use_NN of_IN EPO_NNP versus_CC placebo_NN reached_VBD a_DT such_JJ
        statistical_JJ significance_NN after_IN which_WDT the_DT uncertainty_NN [_NN 9_CD ]_NN
        about_IN the_DT effect_NN of_IN EPO_NNP in_IN cancer-related_JJ anemia_NN could_MD have_VB
        been_VBN considered_VBN resolved_VBN ._.
      
      
        Methods_NNP
        A_DT previous_JJ SR_NNP served_VBD as_IN a_DT basis_NN for_IN location_NN of_IN the_DT
        articles_NNS of_IN interest_NN [_NN 5_CD ]_NN ._. We_PRP also_RB performed_VBD a_DT search_NN of_IN
        MEDLINE_NNP ,_, LILACS_NNP and_CC CANCERLIT_NNP databases_NNS ,_, last_JJ update_NN in_IN
        July_NNP of_IN 2001_CD ,_, using_VBG the_DT optimal_NN search_NN strategy_NN for_IN RCT_NNP for_IN
        use_NN in_IN MEDLINE_NNP [_NN 10_CD ]_NN and_CC LILACS_NNP [_NN 11_CD ]_NN with_IN the_DT additional_JJ
        terms_NNS related_VBN to_TO this_DT review_NN -_: (_( epoetin_NN OR_NNP Erythropoietin_NNP )_)
        and_CC (_( cancer_NN OR_NNP neoplasm_NN )_) ,_, in_IN all_DT fields_NNS ._.
        We_PRP included_VBD only_RB RCTs_NNP that_WDT compared_VBD EPO_NNP versus_CC no_DT
        therapy_NN or_CC placebo_NN in_IN cancer_NN related_VBD anemia_NN ._. We_PRP excluded_VBD
        studies_NNS related_VBN to_TO transplant_VB setting_NN and_CC myelodysplastic_JJ
        syndrome_NN ,_, since_IN the_DT physiopathology_NN of_IN these_DT diseases_NNS is_VBZ
        different_JJ ,_, more_RBR linked_VBN to_TO pancytopenia_NN than_IN to_TO anemia_NN [_NN 1_CD ]_NN
        ._. We_PRP also_RB excluded_VBD trials_NNS that_WDT used_VBD EPO_NNP with_IN the_DT primary_JJ
        objective_NN to_TO magnify_VB hb_NN to_TO improve_VB the_DT efficacy_NN of_IN
        radiotherapy_NN ._.
        Four_CD trials_NNS described_VBD more_JJR than_IN one_CD comparison_NN of_IN
        different_JJ doses_NNS of_IN EPO_NNP with_IN only_RB one_CD control_NN group_NN [_NN 12_CD 13_CD
        14_CD 15_CD ]_NN ._. We_PRP approached_VBD these_DT multi-arm_JJ studies_NNS in_IN two_CD
        different_JJ ways_NNS :_: in_IN the_DT first_JJ ,_, each_DT EPO_NNP arm_NN was_VBD compared_VBN to_TO
        the_DT control_NN arm_NN ._. In_IN the_DT second_JJ we_PRP combined_VBD all_DT active_JJ arms_NNS
        in_IN one_CD ,_, by_IN adding_VBG all_DT EPO_NNP treated_VBD patients_NNS ,_, and_CC analyzed_VBD it_PRP
        against_IN the_DT control_NN ._. Both_DT combinations_NNS achieved_VBN virtually_RB
        the_DT same_JJ result_NN and_CC data_NNS are_VBP presented_VBN using_VBG the_DT second_JJ
        method_NN ._.
        Data_NNP were_VBD abstracted_JJ on_IN patient_NN characteristics_NNS ,_, type_NN of_IN
        tumor_NN ,_, treatment_NN details_NNS and_CC the_DT major_JJ methodological_JJ
        quality_NN dimensions_NNS [_NN 4_CD 7_CD ]_NN (_( see_VB Additional_JJ file_NN 1_LS )_) ._. The_DT end_NN
        point_NN studied_VBN was_VBD the_DT number_NN of_IN patients_NNS requiring_VBG
        transfusions_NNS ._. Results_NNS in_IN a_DT conventional_JJ meta-analysis_JJ were_VBD
        pooled_VBN using_VBG the_DT Peto_NNP 's_POS Odds_NNS Ratio_NNP (_( OR_NNP )_) and_CC relative_JJ risk_NN
        (_( RR_NNP )_) ,_, both_DT in_IN a_DT fixed_VBN effect_NN model_NN [_NN 16_CD ]_NN ._. We_PRP also_RB
        extracted_VBD data_NNS on_IN adverse_JJ effects_NNS of_IN the_DT use_NN of_IN EPO_NNP ._.
        Additional_JJ file_NN
        Table_NNP 1_CD :_: Characteristics_NNP of_IN included_VBD studies_NNS ._.
        Click_NNP here_RB for_IN file_NN
        Heterogeneity_NNP among_IN trials_NNS was_VBD assessed_VBN using_VBG chi-square_JJ
        test_NN (_( chi_NN )_) ._. The_DT possibility_NN of_IN publication_NN bias_NN was_VBD
        assessed_VBN using_VBG the_DT funnel_VB plot_NN method_NN [_NN 17_CD ]_NN ._. To_TO assess_VB
        the_DT reasons_NNS for_IN any_DT heterogeneity_NN found_VBD ,_, we_PRP performed_VBD a_DT
        meta-regression_JJ [_NN 4_CD ]_NN ._. Sensitivity_NNP and_CC subgroup_NN analyses_NNS
        according_VBG to_TO the_DT main_JJ methodological_JJ quality_NN dimensions_NNS [_NN 7_CD
        ]_NN and_CC a_DT number_NN of_IN clinical_JJ criteria_NNS were_VBD also_RB performed_VBN
        (_( see_VB fig_NN 2_CD and_CC 3_LS )_) ._. The_DT results_NNS were_VBD calculated_VBN with_IN
        corresponding_JJ 95_CD %_NN confidence_NN interval_NN (_( 95_CD %_NN CI_NNP )_) ._. When_WRB the_DT
        results_NNS from_IN pooled_VBN data_NNS were_VBD significant_JJ ,_, we_PRP calculated_VBD
        the_DT number_NN of_IN patients_NNS need_VBP to_TO treat_VB (_( NNT_NNP )_) [_NN 18_CD ]_NN in_IN order_NN
        to_TO prevent_VB one_CD transfusion_NN ._. However_RB ,_, the_DT readers_NNS are_VBP
        advised_VBN to_TO exercise_VB due_JJ caution_NN because_IN NNT_NNP and_CC NNH_NNP (_( number_NN
        of_IN patients_NNS to_TO harm_VB )_) are_VBP more_RBR influenced_VBN by_IN the_DT baseline_NN
        risk_NN in_IN a_DT control_NN group_NN than_IN the_DT odds_NNS ratio_NN ._.
        The_DT qualitative_JJ conclusion_NN of_IN the_DT authors_NNS was_VBD assessed_VBN
        using_VBG the_DT method_NN described_VBN by_IN Gilberts_NNP and_CC Colditz_NNP [_NN 19_CD 20_CD
        ]_NN and_CC adapted_VBN to_TO a_DT six_CD point_NN scale_NN ,_, where_WRB 1_CD =_SYM control_NN group_NN
        highly_RB preferred_VBN ,_, 2_CD =_SYM control_NN preferred_VBN to_TO EPO_NNP treatment_NN ,_, 3_CD
        =_SYM about_IN equal_JJ ,_, EPO_NNP a_DT disappointment_NN ,_, 4_CD =_SYM about_IN equal_JJ ,_, EPO_NNP a_DT
        success_NN ,_, 5_CD =_SYM EPO_NNP preferred_VBN to_TO control_VB and_CC 6_CD =_SYM EPO_NNP highly_RB
        preferred_VBN ._.
        Finally_RB ,_, we_PRP performed_VBD a_DT cumulative_JJ meta-analysis_JJ (_( CMA_NNP )_) [_NN
        8_CD ]_NN using_VBG a_DT conservative_JJ approach_NN ,_, setting_VBG the_DT α_NN error_NN at_IN
        1_CD %_NN ,_, with_IN a_DT two_CD tailored_VBN "_'' p_NN "_'' in_IN a_DT random_JJ effects_NNS model_NN [_NN 21_CD
        ]_NN ._. The_DT CMA_NNP allowed_VBD us_PRP to_TO determine_VB the_DT point_NN when_WRB the_DT
        results_NNS achieved_VBD a_DT level_NN of_IN statistical_JJ significance_NN after_IN
        which_WDT we_PRP should_MD expect_VB no_DT changes_NNS in_IN the_DT effect_NN by_IN
        performing_VBG new_JJ trials_NNS ,_, and_CC after_IN which_WDT placebo_NN controlled_VBD
        trials_NNS should_MD not_RB have_VB been_VBN performed_VBN ._. In_IN other_JJ words_NNS :_: CMA_NNP
        allowed_VBD us_PRP to_TO determine_VB the_DT threshold_NN point_NN after_IN which_WDT
        uncertainty_NN about_IN this_DT question_NN should_MD have_VB been_VBN considered_VBN
        resolved_VBN [_NN 9_CD ]_NN ._.
      
      
        Results_NNS
        Thirty-seven_NNP randomized_JJ articles_NNS addressing_VBG the_DT use_NN of_IN
        EPO_NNP in_IN cancer_NN related_VBD anemia_NN were_VBD located_VBN and_CC retrieved_VBN for_IN
        full_JJ text_NN appraisal_NN ._. Twenty_CD one_CD papers_NNS fit_VBP our_PRP$ inclusion_NN
        criteria_NNS ._. Two_CD articles_NNS describing_VBG two_CD small_JJ trials_NNS [_NN 22_CD 23_CD
        ]_NN with_IN a_DT total_NN of_IN 79_CD patients_NNS were_VBD excluded_VBN from_IN our_PRP$
        analysis_NN because_IN they_PRP did_VBD not_RB provide_VB information_NN regarding_VBG
        our_PRP$ end_NN point_NN of_IN interest_NN ._.
        Nineteen_NNP articles_NNS [_NN 2_CD 3_CD 12_CD 13_CD 14_CD 15_CD 24_CD 25_CD 26_CD 27_CD 28_CD 29_CD 30_CD
        31_CD 32_CD 33_CD 34_CD 35_CD 36_CD ]_NN describing_VBG 21_CD trials_NNS (_( see_VB Additional_JJ
        file_NN 1_LS )_) fit_VB our_PRP$ inclusion_NN criteria_NNS ._. One_CD paper_NN [_NN 3_CD ]_NN
        described_VBD three_CD different_JJ trials_NNS ,_, two_CD of_IN which_WDT [_NN 24_CD 26_CD ]_NN
        were_VBD reported_VBN later_RB ,_, in_IN separate_JJ papers_NNS ._. We_PRP included_VBD data_NNS
        from_IN these_DT latest_JJS papers_NNS only_RB ._. Therefore_RB ,_, we_PRP included_VBD 19_CD
        trials_NNS from_IN 19_CD articles_NNS with_IN 1896_CD patients_NNS in_IN cancer_NN
        related_VBD anemia_NN ._. Fourteen_CD trials_NNS with_IN a_DT total_NN of_IN 1511_CD
        patients_NNS described_VBD the_DT use_NN of_IN EPO_NNP in_IN patients_NNS with_IN hb_NN level_NN
        <_NN 11_CD ._. 5_LS g_SYM /_NN dl_NN and_CC five_CD trials_NNS with_IN 369_CD patients_NNS related_VBN to_TO
        hb_NN level_NN >_NN =_SYM 11_CD ._. 5_LS g_SYM /_NN dl_NN ._. Of_IN the_DT latter_JJ ones_NNS ,_, one_CD trial_NN [_NN
        14_CD ]_NN included_VBD patients_NNS with_IN hb_NN ranging_VBG from_IN 10_CD ._. 6_CD to_TO 12_CD ._. 0_CD
        g_SYM /_NN dl_NN ._. The_DT analysis_NN did_VBD not_RB change_VB when_WRB we_PRP excluded_VBD this_DT
        trial_NN in_IN the_DT sensitivity_NN analysis_NN ._.
        The_DT possibility_NN of_IN publication_NN bias_NN was_VBD considered_VBN
        unlikely_JJ according_VBG to_TO the_DT visual_JJ inspection_NN of_IN the_DT funnel_VB
        plot_NN [_NN 17_CD ]_NN ._. The_DT results_NNS of_IN the_DT critical_JJ appraisal_NN
        according_VBG to_TO the_DT most_RBS important_JJ methodological_JJ quality_NN
        dimensions_NNS of_IN each_DT article_NN are_VBP shown_VBN in_IN (_( see_VB Additional_JJ
        file_NN 1_LS )_) ._. No_DT single_JJ trial_NN met_VBD all_DT methodological_JJ quality_NN
        criteria_NNS ._. All_DT trials_NNS scored_VBD five_CD or_CC six_CD on_IN the_DT six_CD point_NN
        Gilbert_NNP [_NN 19_CD ]_NN and_CC Colditz_NNP [_NN 20_CD ]_NN scales_NNS ,_, denoting_VBG strong_JJ
        qualitative_JJ support_NN in_IN favor_NN of_IN EPO_NNP (_( (_( see_VB Additional_JJ file_NN
        1_LS )_) )_) ._.
        The_DT meta-analysis_JJ of_IN the_DT 19_CD trials_NNS (_( Fig_NNP 1_CD and_CC 3_LS )_) showed_VBD a_DT
        significant_JJ beneficial_JJ effect_NN of_IN EPO_NNP in_IN diminishing_VBG the_DT
        number_NN of_IN patients_NNS requiring_VBG transfusion_NN [_NN OR_NNP =_SYM 0_CD ._. 41_CD ;_: 95_CD %_NN CI_NNP :_:
        0_CD ._. 33_CD to_TO 0_CD ._. 5_CD ;_: p_NN <_NN 0_CD ._. 00001_CD ]_NN ,_, without_IN statistical_JJ
        heterogeneity_NN [_NN chi_NN =_SYM 23_CD ._. 46_CD ;_: df_NN =_SYM 18_CD ;_: p_NN >_NN 0_CD ._. 1_CD ]_NN ._. When_WRB we_PRP
        used_VBD relative_JJ risk_NN (_( fig_NN 3_LS )_) as_IN a_DT summary_NN point_NN estimate_NN in_IN
        the_DT meta-analysis_JJ ,_, the_DT results_NNS remained_VBD significant_JJ [_NN RR_NNP =_SYM
        0_CD ._. 61_CD ;_: 95_CD %_NN CI_NNP :_: 0_CD ._. 54_CD to_TO 0_CD ._. 68_CD ;_: p_NN <_NN 0_CD ._. 00001_CD ]_NN ,_, but_CC now_RB with_IN
        significant_JJ statistical_JJ heterogeneity_NN :_: [_NN chi_NN =_SYM 37_CD ._. 56_CD ;_: df_NN =_SYM
        18_CD ;_: p_NN =_SYM 0_CD ._. 0044_CD ]_NN ._. However_RB ,_, when_WRB the_DT study_NN by_IN Porter_NNP et_CC al_NN [_NN
        29_CD ]_NN was_VBD removed_VBN from_IN the_DT analysis_NN ,_, heterogeneity_NN
        disappeared_VBD from_IN the_DT analysis_NN ,_, and_CC the_DT analysis_NN according_VBG
        to_TO OR_NNP or_CC RR_NNP did_VBD not_RB differ_VB ._. This_DT is_VBZ likely_JJ because_IN in_IN this_DT
        small_JJ study_NN including_VBG 10_CD patients_NNS in_IN each_DT group_NN ,_, event_NN rate_NN
        was_VBD so_RB high_JJ with_IN all_DT but_CC one_CD patient_NN receiving_VBG
        transfusion_NN ._.
        To_TO further_VB explain_VB heterogeneity_NN ,_, we_PRP also_RB performed_VBD a_DT
        metaregression_NN [_NN 4_CD ]_NN ._. The_DT variables_NNS related_VBN to_TO the_DT design_NN
        and_CC clinical_JJ features_NNS which_WDT possible_JJ could_MD affect_VB the_DT
        treatment_NN effect_NN of_IN EPO_NNP were_VBD entered_VBN in_IN the_DT equation_NN (_( see_VB
        Additional_JJ file_NN 1_LS )_) We_PRP found_VBD no_DT statistically_RB significant_JJ
        association_NN between_IN any_DT of_IN the_DT variables_NNS with_IN the_DT treatment_NN
        effect_NN of_IN EPO_NNP when_WRB all_DT data_NNS were_VBD simultaneously_RB entered_VBN in_IN
        a_DT multiregression_NN equation_NN (_( data_NNS not_RB shown_VBN )_) ._. However_RB ,_, when_WRB a_DT
        stepwise_NN regression_NN model_NN was_VBD used_VBN ,_, two_CD variables_NNS emerged_VBD
        of_IN the_DT potential_JJ significance_NN which_WDT could_MD explain_VB most_JJS the_DT
        heterogeneity_NN of_IN our_PRP$ results_NNS :_: (_( in_IN )_) adequacy_NN of_IN allocation_NN
        concealment_NN (_( p_NN =_SYM 0_CD ._. 026_CD )_) and_CC Hb_NNP cut-off_JJ value_NN of_IN 11_CD ._. 5_LS g_SYM /_NN dl_NN
        (_( p_NN =_SYM 0_CD ._. 046_CD )_) ._. The_DT between_IN study_NN variation_NN (_( tau_NN 2_CD estimate_NN )_)
        was_VBD 0_CD ._. 0372_CD for_IN the_DT model_NN containing_VBG no_DT variables_NNS (_( i_NNP ._. e_SYM ._. the_DT
        simple_JJ meta-analysis_JJ )_) ;_: this_DT was_VBD reduced_VBN to_TO almost_RB zero_CD in_IN
        the_DT final_JJ model_NN ._. In_IN addition_NN ,_, most_RBS likely_JJ explanation_NN of_IN
        heterogeneity_NN seen_VBN in_IN our_PRP$ study_NN is_VBZ related_VBN to_TO a_DT small_JJ
        sample_NN size_NN of_IN the_DT individual_JJ trials_NNS resulting_VBG in_IN random_JJ
        fluctuation_NN of_IN the_DT effect_NN between_IN the_DT studies_NNS ._. When_WRB we_PRP
        divided_VBD the_DT trials_NNS according_VBG to_TO the_DT hb_NN level_NN ,_, using_VBG 11_CD ._. 5_LS
        g_SYM /_NN dl_NN as_IN a_DT cut-off_JJ point_NN ,_, the_DT results_NNS remained_VBD essentially_RB
        unchanged_JJ (_( i_NNP ._. e_SYM ._. highly_RB significant_JJ in_IN favor_NN of_IN EPO_NNP )_) (_( fig_NN
        2_CD and_CC 3_LS )_) ._.
        Thus_RB ,_, it_PRP appears_VBZ that_IN the_DT effect_NN of_IN EPO_NNP is_VBZ a_DT rather_RB
        robust_JJ despite_IN heterogeneity_NN noted_VBD in_IN the_DT meta-analysis_JJ
        Sensitivity_NNP and_CC subgroup_NN analyses_NNS according_VBG to_TO clinical_JJ
        and_CC methodological_JJ quality_NN dimensions_NNS (_( Fig_NNP 2_CD and_CC 3_LS )_) showed_VBD
        consistency_NN in_IN the_DT results_NNS ,_, favoring_VBG the_DT use_NN of_IN EPO_NNP ._.
        Statistical_NNP heterogeneity_NN was_VBD noted_VBN for_IN some_DT of_IN these_DT
        comparisons_NNS (_( see_VB fig_NN 2_CD and_CC 3_LS )_) ._. It_PRP was_VBD related_VBN to_TO the_DT
        magnitude_NN of_IN the_DT treatment_NN effect_NN and_CC not_RB to_TO its_PRP$
        significance_NN ,_, since_IN in_IN all_DT trials_NNS the_DT point_NN estimate_NN of_IN the_DT
        effect_NN favored_VBD EPO_NNP ._. A_DT stepwise_NN metaregression_NN analysis_NN did_VBD
        point_NN to_TO the_DT possibility_NN that_DT treatment_NN effect_NN could_MD have_VB
        been_VBN exaggerated_VBN by_IN inadequacy_NN in_IN allocation_NN concealment_NN
        and_CC that_IN larger_JJR treatment_NN effects_NNS are_VBP seen_VBN at_IN hb_NN level_NN <_NN
        11_CD ._. 5_LS g_SYM /_NN dl_NN ._. The_DT heterogeneity_NN was_VBD more_RBR common_JJ when_WRB we_PRP used_VBD
        RR_NNP than_IN when_WRB we_PRP used_VBD OR_NNP ._.
        The_DT overall_JJ result_NN by_IN pooling_VBG all_DT trials_NNS indicates_VBZ that_IN
        for_IN each_DT 5_CD cancer_NN patients_NNS (_( 95_CD %_NN CI_NNP :_: 4_CD to_TO 7_CD )_) using_VBG EPO_NNP ,_, one_CD
        patient_NN will_MD avoid_VB transfusion_NN ._. This_DT result_NN is_VBZ maintained_VBN
        when_WRB we_PRP separately_RB analyzed_VBD the_DT trials_NNS that_WDT included_VBD
        patients_NNS with_IN hb_NN level_NN <_NN 11_CD ._. 5_LS g_SYM /_NN dl_NN (_( NNT_NNP =_SYM 5_CD ;_: 95_CD %_NN CI_NNP :_: 4_CD
        to_TO 8_CD )_) and_CC Hb_NNP >_NN 11_CD ._. 5_LS g_SYM /_NN dl_NN (_( NNT_NNP =_SYM 5_CD ;_: 95_CD %_NN CI_NNP :_: 3_CD to_TO 9_CD )_) ._.
        These_DT NNT_NNP should_MD be_VB analyzed_VBN carefully_RB ,_, since_IN they_PRP were_VBD
        calculated_VBN from_IN a_DT pool_NN of_IN data_NNS that_IN in_IN some_DT analysis_NN were_VBD
        not_RB homogeneous_JJ ._.
        We_PRP also_RB performed_VBD a_DT CMA_NNP ,_, (_( fig_NN 4_LS )_) using_VBG a_DT conservative_JJ
        approach_NN (_( i_NNP ._. e_SYM ._. setting_VBG α_NN error_NN at_IN 1_CD %_NN )_) ._. Our_PRP$ CMA_NNP demonstrated_VBD
        that_IN by_IN 1995_CD a_DT high_JJ level_NN of_IN significance_NN [_NN OR_NNP =_SYM 0_CD ._. 52_CD ;_:
        99_CD %_NN CI_NNP :_: 0_CD ._. 28_CD to_TO 0_CD ._. 97_CD ;_: p_NN =_SYM 0_CD ._. 0068_CD ]_NN ;_: [_NN RR_NNP =_SYM 0_CD ._. 69_CD ;_: 99_CD %_NN CI_NNP :_: 0_CD ._. 53_CD
        to_TO 0_CD ._. 90_CD ;_: p_NN =_SYM 0_CD ._. 0003_CD ]_NN about_IN the_DT benefit_NN of_IN EPO_NNP on_IN reducing_VBG
        the_DT use_NN of_IN blood_NN transfusions_NNS had_VBD been_VBN achieved_VBN ._. Beyond_IN
        this_DT point_NN ,_, all_DT new_JJ trials_NNS only_RB improved_VBD the_DT precision_NN ,_,
        without_IN adding_VBG any_DT additional_JJ useful_JJ information_NN ._. We_PRP
        estimated_VBD that_IN 1240_CD patients_NNS ,_, representing_VBG 65_CD %_NN of_IN the_DT total_JJ
        number_NN of_IN cancer_NN patients_NNS who_WP participated_VBD in_IN EPO_NNP studies_NNS ,_,
        were_VBD enrolled_VBN in_IN 13_CD placebo-controlled_JJ randomized_JJ studies_NNS
        that_WDT were_VBD reported_VBN after_IN 1995_CD ._.
        The_DT previous_JJ SR_NNP [_NN 5_CD ]_NN concluded_VBD that_IN it_PRP was_VBD impossible_JJ
        to_TO reasonably_RB distinguish_VB between_IN adverse_JJ events_NNS related_VBN to_TO
        EPO_NNP and_CC concurrent_JJ treatments_NNS ._. We_PRP also_RB tried_VBD to_TO extract_VB
        data_NNS on_IN adverse_JJ events_NNS ,_, but_CC were_VBD unable_JJ to_TO make_VB a_DT
        reasonable_JJ approach_NN due_JJ to_TO the_DT poor_JJ reporting_NN ._. Therefore_RB ,_,
        we_PRP decided_VBD not_RB to_TO tabulate_NN data_NNS on_IN adverse_JJ events_NNS and_CC
        perform_VB quantitative_JJ pooling_VBG ._.
      
      
        Discussion_NNP
        According_VBG to_TO our_PRP$ overall_JJ analysis_NN ,_, administration_NN of_IN EPO_NNP
        is_VBZ related_VBN to_TO an_DT average_JJ 59_CD %_NN reduction_NN in_IN odds_NNS of_IN requiring_VBG
        a_DT transfusion_NN ._. A_DT previous_JJ SR_NNP [_NN 5_CD 6_CD ]_NN pooled_VBN 12_CD trials_NNS that_WDT
        used_VBD subcutaneous_JJ EPO_NNP (_( all_DT also_RB included_VBN in_IN our_PRP$ analysis_NN )_)
        in_IN a_DT Bayesian_NNP MA_NNP reached_VBD results_NNS similar_JJ [_NN OR_NNP =_SYM 0_CD ._. 38_CD ;_: 95_CD %_NN CI_NNP :_:
        0_CD ._. 28_CD to_TO 0_CD ._. 51_CD ]_NN to_TO ours_PRP ._. We_PRP could_MD also_RB demonstrate_VB
        consistency_NN of_IN the_DT results_NNS when_WRB analyzed_VBD according_VBG to_TO OR_NNP ,_,
        RR_NNP ,_, various_JJ quality_NN dimensions_NNS and_CC many_JJ different_JJ clinical_JJ
        settings_NNS (_( fig_NN 2_CD and_CC 3_LS )_) ._.
        Due_JJ to_TO these_DT EPO_NNP effects_NNS ,_, patients_NNS with_IN cancer_NN are_VBP
        expected_VBN to_TO have_VB direct_JJ benefits_NNS through_IN fewer_JJR transfusions_NNS
        and_CC lower_JJR exposure_NN to_TO anemia_NN effects_NNS ._. Furthermore_RB ,_, all_DT
        patients_NNS will_MD benefit_VB indirectly_RB through_IN conservation_NN of_IN
        the_DT blood_NN supply_NN ._.
        The_DT use_NN of_IN RR_NNP as_IN summary_NN statistics_NNS is_VBZ less_RBR robust_JJ than_IN
        OR_NNP [_NN 4_CD ]_NN and_CC in_IN this_DT case_NN resulted_VBD in_IN greater_JJR heterogeneity_NN
        than_IN the_DT analysis_NN based_VBN on_IN OR_NNP (_( see_VB fig_NN 2_CD and_CC 3_LS )_) ._. The_DT
        estimate_NN the_DT effects_NNS of_IN EPO_NNP using_VBG RR_NNP indicated_VBD a_DT smaller_JJR
        effect_NN than_IN OR_NNP but_CC both_DT results_NNS were_VBD significant_JJ (_( p_NN <_NN
        0_CD ._. 0001_CD in_IN both_DT analysis_NN )_) ._. However_RB ,_, when_WRB events_NNS are_VBP common_JJ ,_,
        the_DT OR_NNP may_MD overestimate_NN the_DT effect_NN of_IN treatment_NN [_NN 4_CD ]_NN ._. Due_JJ
        to_TO these_DT characteristics_NNS of_IN the_DT analysis_NN ,_, we_PRP choose_VBP to_TO show_VB
        both_DT (_( OR_NNP and_CC RR_NNP )_) as_IN a_DT summary_NN statistics_NNS ._. Nevertheless_RB ,_, we_PRP
        should_MD mention_VB (_( see_VB the_DT RESULTS_NNP )_) that_IN the_DT most_JJS of_IN
        heterogeneity_NN could_MD be_VB explained_VBN by_IN high_JJ transfusion_NN rates_NNS
        in_IN the_DT trial_NN by_IN Porter_NNP et_CC al_NN ._. and_CC inadequacy_NN of_IN allocation_NN
        concealment_NN in_IN EPO_NNP trials_NNS ._. Similarly_RB ,_, it_PRP appears_VBZ that_IN the_DT
        larger_JJR treatment_NN effects_NNS are_VBP seen_VBN when_WRB EPO_NNP is_VBZ given_VBN in_IN the_DT
        patients_NNS with_IN hb_NN >_NN 11_CD ._. 5_LS g_SYM /_NN dl_NN ._.
        Because_IN it_PRP was_VBD not_RB possible_JJ to_TO extract_VB data_NNS on_IN quality_NN
        of_IN life_NN (_( QOL_NNP )_) ,_, this_DT issue_NN was_VBD not_RB addressed_VBN here_RB ._. However_RB ,_,
        a_DT recent_JJ systematic_JJ review_NN by_IN Bottomley_NNP et_CC al_NN [_NN 37_CD ]_NN
        indicated_VBD that_IN solid_JJ evidence_NN about_IN the_DT effect_NN of_IN EPO_NNP on_IN
        this_DT end_NN point_NN is_VBZ lacking_VBG ._. We_PRP should_MD also_RB mention_VB that_IN the_DT
        high_JJ cost_NN of_IN EPO_NNP has_VBZ deterred_VBD its_PRP$ widespread_JJ acceptance_NN [_NN 5_CD
        ]_NN and_CC more_JJR studies_NNS using_VBG economic_JJ analysis_NN should_MD be_VB done_VBN
        to_TO address_VB the_DT issue_NN if_IN the_DT use_NN of_IN EPO_NNP is_VBZ
        cost-effective_JJ ._.
        A_DT previous_JJ SR_NNP [_NN 5_CD 6_CD ]_NN found_VBD no_DT increased_VBN incidence_NN of_IN
        adverse_JJ events_NNS of_IN EPO_NNP when_WRB compared_VBN with_IN controls_NNS ._. We_PRP also_RB
        did_VBD not_RB find_VB any_DT side_NN effect_NN of_IN EPO_NNP consistently_RB reported_VBD
        among_IN trials_NNS ._.
        Our_PRP$ main_JJ goal_NN here_RB is_VBZ to_TO stress_VB that_IN the_DT basic_JJ ethical_JJ
        requirement_NN to_TO randomize_NN patients_NNS in_IN clinical_JJ trials_NNS is_VBZ
        that_IN physicians_NNS and_CC patients_NNS must_MD not_RB have_VB preferences_NNS for_IN
        any_DT of_IN the_DT therapies_NNS considered_VBD i_NNP ._. e_SYM ._. they_PRP should_MD be_VB in_IN the_DT
        state_NN of_IN uncertainty_NN or_CC equipoise_NN [_NN 9_CD ]_NN ._. If_IN uncertainty_NN
        does_VBZ not_RB exist_VB ,_, it_PRP is_VBZ felt_VBN to_TO be_VB unethical_JJ to_TO ask_VB patients_NNS
        to_TO participate_VB in_IN RCTs_NNP [_NN 9_CD ]_NN ._.
        To_TO assess_VB if_IN uncertainty_NN regarding_VBG a_DT clinical_JJ question_NN
        exists_VBZ ,_, researchers_NNS should_MD evaluate_VB the_DT totality_NN of_IN
        pre-existing_JJ knowledge_NN :_: if_IN we_PRP already_RB knew_VBD that_IN one_CD
        treatment_NN is_VBZ superior_JJ to_TO another_DT ,_, nothing_NN new_JJ could_MD be_VB
        learned_VBN and_CC we_PRP would_MD unnecessarily_RB expose_VB our_PRP$ patients_NNS to_TO
        already_RB known_VBN inferior_JJ treatment_NN by_IN performing_VBG a_DT new_JJ trial_NN ._.
        We_PRP showed_VBD here_RB that_IN if_IN a_DT SR_NNP /_NN CMA_NNP had_VBD been_VBN used_VBN to_TO formally_RB
        address_VB the_DT uncertainty_NN regarding_VBG the_DT effect_NN of_IN EPO_NNP in_IN
        cancer_NN patients_NNS ,_, this_DT uncertainty_NN could_MD have_VB been_VBN
        conservatively_RB considered_VBN resolved_VBN (_( Fig_NNP 4_LS )_) since_IN 1995_CD ._. Our_PRP$
        findings_NNS suggest_VBP that_IN 65_CD %_NN of_IN the_DT cancer_NN patients_NNS included_VBN
        in_IN this_DT SR_NNP participated_VBD in_IN placebo_NN controlled_VBD clinical_JJ
        trials_NNS that_WDT were_VBD reported_VBN after_IN EPO_NNP was_VBD shown_VBN to_TO be_VB
        superior_JJ to_TO placebo_NN ._. Had_VBD a_DT CMA_NNP been_VBN performed_VBN
        prospectively_RB ,_, it_PRP is_VBZ possible_JJ that_IN clinical_JJ trialists_NNS may_MD
        have_VB decided_VBN against_IN initiating_VBG 13_CD clinical_JJ trials_NNS ._. We_PRP
        should_MD note_VB that_IN we_PRP analyzed_VBD trials_NNS according_VBG to_TO date_NN of_IN
        their_PRP$ report_NN ._. It_PRP is_VBZ conceivable_JJ that_IN some_DT trials_NNS were_VBD
        initiated_VBN before_IN 1995_CD ,_, but_CC were_VBD reported_VBN after_IN 1995_CD ._.
        However_RB ,_, this_DT only_RB means_VBZ that_IN the_DT uncertainty_NN about_IN the_DT
        role_NN of_IN EPO_NNP could_MD have_VB been_VBN solved_VBN even_RB earlier_RBR (_( if_IN these_DT
        patients_NNS were_VBD available_JJ for_IN CMA_NNP or_CC a_DT large_JJ RCT_NNP )_) ._. For_IN
        example_NN ,_, if_IN all_DT 656_CD patients_NNS included_VBN in_IN randomized_JJ studies_NNS
        up_IN to_TO 1995_CD had_VBD participated_VBN in_IN only_RB one_CD ,_, large_JJ ,_, randomized_JJ
        study_NN ,_, the_DT uncertainty_NN about_IN EPO_NNP could_MD have_VB been_VBN solved_VBN
        earlier_RBR ._. An_DT alternative_JJ approach_NN to_TO large_JJ studies_NNS in_IN
        solving_VBG uncertainty_NN is_VBZ to_TO use_VB CMA_NNP to_TO monitor_VB accumulation_NN
        of_IN treatment_NN effects_NNS in_IN clinical_JJ trials_NNS [_NN 38_CD ]_NN ._. The_DT
        technique_NN of_IN CMA_NNP is_VBZ a_DT powerful_JJ scientific_JJ instrument_NN to_TO
        assess_VB the_DT significance_NN of_IN accumulated_VBN knowledge_NN [_NN 8_CD 38_CD ]_NN ._.
        In_IN more_JJR than_IN 100_CD CMA_NNP performed_VBD ,_, there_EX has_VBZ never_RB been_VBN a_DT
        single_JJ case_NN where_WRB the_DT point_NN estimate_NN switched_VBD to_TO indicate_VB
        the_DT opposite_JJ effect_NN ,_, once_RB the_DT difference_NN between_IN treatments_NNS
        reached_VBD statistical_JJ significance_NN [_NN 8_CD ]_NN ._.
      
      
        Conclusion_NNP
        EPO_NNP is_VBZ highly_RB effective_JJ for_IN cancer-related_JJ anemia_NN ._. This_DT
        effect_NN could_MD have_VB been_VBN detected_VBN in_IN 1995_CD if_IN CMA_NNP had_VBD been_VBN
        performed_VBN at_IN that_DT time_NN ._. The_DT techniques_NNS of_IN CMA_NNP should_MD be_VB
        used_VBN more_RBR frequently_RB in_IN the_DT future_NN to_TO preserve_VB "_'' the_DT
        uncertainty_NN principle_NN "_'' [_NN 9_CD ]_NN and_CC protect_VB patients_NNS who_WP
        consent_NN to_TO be_VB randomized_JJ in_IN clinical_JJ trials_NNS ._.
      
      
        Competing_VBG interests_NNS
        No_DT funding_NN or_CC honoraria_NN were_VBD provided_VBN for_IN this_DT work_NN to_TO
        any_DT of_IN the_DT authors_NNS ._. CB_NNP and_CC BD_NNP served_VBD as_IN consultants_NNS for_IN the_DT
        US_NNP manufacturers_NNS of_IN erythropoietin_NN (_( Amgen_NNP ,_, Ortho_NNP )_) and_CC also_RB
        received_VBD their_PRP$ unrestricted_JJ support_NN for_IN organization_NN of_IN
        educational_JJ seminars_NNS unrelated_JJ to_TO the_DT use_NN of_IN
        erythropoietin_NN ._.
      
      
        Authors_NNP '_'' contributions_NNS
        OC_NNP conceptualized_JJ the_DT study_NN ,_, defined_VBD the_DT protocol_NN ,_,
        extracted_VBN and_CC analyzed_VBN data_NNS ,_, wrote_VBD the_DT draft_NN and_CC approved_VBN
        the_DT final_JJ version_NN of_IN the_DT paper_NN ._. JRD_NNP extracted_VBD data_NNS ,_,
        contributed_VBD to_TO the_DT protocol_NN writing_VBG ,_, extracted_VBN and_CC analyzed_VBN
        data_NNS ,_, contributed_VBD to_TO the_DT drafts_NNS and_CC approved_VBD the_DT final_JJ
        version_NN of_IN the_DT paper_NN ._. CLB_NNP analyzed_VBD data_NNS ,_, took_VBD an_DT active_JJ
        participation_NN on_IN the_DT writing_NN of_IN all_DT versions_NNS of_IN the_DT draft_NN
        and_CC approved_VBN the_DT final_JJ version_NN of_IN the_DT paper_NN ._. BD_NNP
        conceptualized_JJ the_DT study_NN ,_, defined_VBD the_DT protocol_NN ,_, extracted_VBN
        and_CC analyzed_VBN data_NNS ,_, wrote_VBD the_DT draft_NN and_CC approved_VBN the_DT final_JJ
        version_NN of_IN the_DT paper_NN ._.
      
    
  
